Abstract: The present invention provides, among other things, method of treating epidermolysis bullosa including administering to a subject suffering from epidermolysis bullosa an angiotensin (1-7) peptide. In some embodiments, the present invention also provides methods of treating a complication of epidermolysis bullosa including administering to a subject suffering from one or more complications of epidermolysis bullosa an angiotensin (1-7) peptide, wherein the administration results in a reduction in the intensity, severity, duration, or frequency of at least one symptom or feature of the one or more complications of epidermolysis bullosa.

Abstract: The present invention provides, among other things, methods of treating a muscular dystrophy including administering to a subject suffering from or susceptible to a muscular dystrophy an angiotensin (1-7) peptide. The present invention is, in part, based on the unexpected discovery that administration of an angiotensin (1-7) peptide in a muscular dystrophy animal model reduces fibrosis, restores locomotor activity and restores sympathovagal balance, which are characteristic symptoms in patients suffering from muscular dystrophy. Thus, the present invention provides a new and more effective therapy for muscular dystrophy. In some embodiments, an angiotensin (1-7) peptide includes the naturally occurring angiotensin (1-7) amino acid sequence of Asp1-Arg2-Val3-Tyr4-Ile5-His6-Pro7 (SEQID NO:1). In some embodiments, the angiotensin (1-7) peptide is a functional equivalent of SEQ ID NO:1. In some embodiments, the linear peptide has an amino acid sequence of Asp1-Arg2-Val3-Ser4-Ile5-H?is6-Cys7 (SEQ ID NO:2).

Abstract: The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of Marfan Syndrome and/or a Marfan-related disorder is reduced in intensity, severity, duration, or frequency or has delayed in onset.

Abstract: The present invention relates to the use of the anti-megakaryocytic agent anagrelide, or a therapeutically active metabolite thereof, in the prevention or treatment of metastatic disease in cancer patients displaying paraneoplastic thrombocytosis.

Abstract: The present disclosure relates to a buck lure comprising an absorbable pad infused with deer urine and freeze-dried rendering the urine inert. When the pad is hydrated, the scent of the pad emits a scent which lures deer to the site from which the scent is emanating.

Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.

Abstract: The present invention provides, among other things, methods and compositions for treating brain conditions. In some embodiments, the methods include administering to a subject suffering from or susceptible to a brain condition an angiotensin (1-7) peptide via either an intravenous or subcutaneous route of administration.

Abstract: The present invention provides, among other things, methods and compositions for treating brain conditions. In some embodiments, the methods include administering to a subject suffering from or susceptible to a brain condition an angiotensin (1-7) peptide via either an intravenous or subcutaneous route of administration.

Abstract: The present invention provides, among other things, methods and compositions for treating brain-derived neurotrophic factor (BDNF)-related conditions. In some embodiments, the methods include administering to a subject suffering form or susceptible to a BDNF-related condition an angiotensin (1-7) peptide, including both linear and/or cyclic peptides, functional equivalents, analogs and/or derivatives thereof and/or a non-peptidic angiotensin (1-7) receptor agonist. The present invention is based, in part, on the surprising discovery that angiotensin (1-7) peptides can stimulate the production of BDNF in neuronal and endothelial cells.

Abstract: A hierarchical compression tester and associated method employs a grid-based storage capacity wherein a storage unit is defined by a grouping of data blocks. Each data block is stored in one of a plurality of storage devices. Each stored data block has a data portion and a data integrity field (DIF) including a data reliability qualifier (DRQ) indicating whether the respective data portion is valid. The tester also has a logical device allocation map that includes a storage unit descriptor array that identifies one or more storage units corresponding to a selected logical address. The logical device allocation map has a DIF array that identifies whether any of the data blocks in the one or more storage units corresponding to the selected logical address includes invalid data.

Abstract: The present invention provides, among other things, method of treating stroke including a step of administering an angiotensin (1-7) peptide to a subject suffering from a stroke, approximately 24 hours after the stroke. In some embodiments, treatment begins more than 24 hours after the stroke. In some embodiments, administration of an angiotensin (1-7) peptide results in a reduction in the intensity, severity, duration, and/or frequency of at least one symptom or feature of the one or more complications of stroke.

Abstract: The present invention provides, among other things, methods and compositions for treating or preventing fibrotic diseases, disorders or conditions based on Angiotensin (1-7) polypeptides, and analogs or derivatives thereof. In some embodiments, compositions and methods for treating or preventing pulmonary fibrosis, pulmonary hypertension, chronic obstructive pulmonary disease (COPD), asthma, cystic fibrosis, kidney fibrosis, liver fibrosis, systemic sclerosis, post-surgical adhesions, accelerating wound healing, and reducing or preventing scar formation are provided.

Abstract: The present invention provides, among other things, methods of treating a muscular dystrophy including administering to a subject suffering from or susceptible to a muscular dystrophy an angiotensin (1-7) peptide.

Abstract: The present invention provides, among other things, methods of treating Marfan Syndrome and/or a Marfan-related disorder including administering to a subject suffering from or susceptible to Marfan Syndrome and/or a Marfan-related disorder an angiotensin (1-7) peptide. In some embodiments, the angiotensin (1-7) peptide is administered at an effective dose periodically at an administration interval such that at least one symptom or feature of Marfan Syndrome and/or a Marfan-related disorder is reduced in intensity, severity, duration, or frequency or has delayed in onset.

Abstract: An adjustable mounting assembly for attaching an attachment end of a first beam member to a second beam member. The adjustable mounting assembly includes a first bracket attachable to the first beam member; a second bracket attachable to the second beam member; and a point of attachment where the first and second brackets are attached to each other. The adjustable mounting assembly is configured to allow a position of the first beam member to be adjusted relative to the second beam member.

Abstract: The present invention provides, among other things, novel peptides and compositions for treating disease.

Abstract: The present invention provides various formulations for oral delivery of angiotensin peptides.